Hydroxypyridinone derivatives: Synthesis and cytotoxic evaluation

Journal of Reports in Pharmaceutical Sciences

Volumn 2, Issue 1, 2013, Pages 5-15

  Sadeghi Aliabadi, Hojjat ^a   Saghaie, Lotfollah ^a   Tadayonnia, Nariman ^b   Mirian, Mina ^b  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

3 Hydroxypyridin 4 ones; Iron chelating agents; Lipophilicity; MCF 7 and MDA MB 231 cells; MTT assay

Indexed keywords

EID: 84890085607     PISSN: 23221232     EISSN: 23225106     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. [1] Corce CM. Oncogenes and cancer. N Engl J Med. 2008;358:502-511.
2. [2] Kumar P, Clark M. Clinical medicine. 8th ed. Oxford: W.B. Saunder, 2012.
3. [3] Buss JL, Greene BT, Turner J, Torti FM, Torti SV. Iron chelators in cancer chemotherapy.2004; 41:623-635.
4. [4] Richardson DR. Iron chelators as therapeutic agents for the treatment of cancer. 2002;42:267-281
5. [5] Liu ZD, Hider RC. The development of iron chelators for clinical use. Med Res Rev. 2003;22:26-64
6. [6] Brittenham GM. Iron chelating therapy for transfusional iron overload. N Engl J Med. 2011;364:146-156.
7. [7] Rai BL, Dekhordi LS, Khodr H, Jin Y, Liu ZD, Hider RC. Synthesis, physicochemical properties and evaluation of N-substituted-2 alkyl-3-hydroxy-4(1H)-pyridinones. J Med Chem. 1998;41:3347-3359.
8. [8] Kolberg M, Strand KR, Graff P, Andersson KK. Structure, function, and mechanism of ribonucleotide reductase. Biochim Biophys Acta. 2004;1699:1-34.
9. [9] Shao J, Zhou B, Chu B, Yen Y. Ribonucleotid reductase inhibitors and future drug design. Curr Cancer Drug. 2006;6:409-431.
10. [10] Hider RC, Kontoghiorghes G, Silver J, Inventors; 1-hydroxy-pyridin-2-ones. UK Patent GB2136807A, 1984a.
11. [11] Hider RC, Kontoghiorghes G., Silver J, Stockham MA, Inventors; 3-hydroxypyridin-2-ones. UK Patent GB2146989A, 1984b.
12. [12] Hider RC, Kontoghiorghes G, Silver J, Stockham MA, Inventors; 3-hydroxypyridin-4-ones. UK Patent GB2146990A, 1984c.
13. [13] Dobbin PC, Hider RC. Iron chelation therapy. Chem Br. 1990; 6:565-568.
14. [14] Dobbin PS, Hider RC, Hall AD, Taylor PD, Sarpong P, Porter JB, Xiao G, Vanderhelm D. Synthesis, physicochemical properties, and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4(1h) pyridinones: orally active iron chelators with clinical potential. Med chem.1993;36:2448-2458.
15. [15] Saghaie L, Sadeghi-aliabadi H, Kafiri M. Synthesis and biological evaluation of bidentate 3-hydroxypyridin-4-ones iron chelating agents. Res Pharm Sci. 2011;6:117-122.
16. [16] Sadeghi-aliabadi H, Tabarzadi M, Zarghi A. Synthesis and cytotoxic evaluation of two novel anthraquinone derivatives. IL Farmaco. 2004;59:645-649.
17. [17] Saghaie L, Hider RC, Mostafavi S. Comparison automated continuous flow method with shake-flask method in determining partition coefficients of bidentate hydroxyl pyridinone ligands. Daru. 2003;11:38-48.
18. [18] Wolfenden R, Radzicka A. On the probability of finding a water molecule in a nonpolar cavity. Science. 1994;265:936-937.
19. [19] Harris RLN. Potential wool growth inhibitors.Improved synthesis of mimosine and related 4(1H)-pyridinones. Aust J Chem. 1976;29:1329-1334.
20. [20] Saghaie L .Design of orally active iron (III) chelators for clinical use. Ph.D Thesis, King’s College London, 1996.
21. [21] Habgood MD, Liu ZD, Dehkordi LS, Khodr HH, Abbott J, Hider RC. Investigation into the correlation between the structure of hydroxyl pyridinones and bloodbrain barrier permeability. Biochem Pharmacol. 1999;57:1305-1310.
22. [22] Thomas F, Baret P, Imbert D, Pierre JL, Serratrice G. Partition coefficients (free ligands and their iron III complexes) and lipophilic behavior of new abiotic chelators. Correlation to biological activity. Bioorg Med Chem Lett. 1999;9:3035-3040.
23. [23] Gaboriau F, Leray AM, Ropert M, Gouffier L, Cannie I, Troadec MB, et al. Effects of deferasirox and deferiprone on cellular iron load in the human hepatoma cell line HepaRG. Biometals. 2010;23:231-245.